摘要
目的研究非小细胞肺癌(NSCLC)诊断中血浆miRNA-155、miRNA-625测定的临床价值。方法采用回顾性分析,研究对象为2018年1月至2020年1月首都医科大学附属北京世纪坛医院收治的98例NSCLC患者与110例肺部良性疾病患者,分别设定为研究组与对照组。比较2组血浆miRNA-155、miRNA-625表达水平与血清癌胚抗原水平,分析研究组患者血浆miRNA-155、miRNA-625表达与临床病理特征(性别、年龄、TNM分期、分化程度、组织学类型、吸烟)相关性,并比较miRNA-155、miRNA-625、血清癌胚抗原诊断NSCLC的准确性、阴性预测值、阳性预测值、特异度及敏感度。结果研究组血浆miRNA-155、血清癌胚抗原水平为(5.76±3.81)、(6.62±5.41)μg/L,高于对照组[(1.98±1.71)、(3.94±1.53)μg/L],血浆miRNA-625(0.53±0.43)水平低于对照组(1.08±0.61),差异均有统计学意义(P<0.05)。研究组Ⅰ、Ⅱ期患者的血浆miRNA-155表达水平(4.87±3.46)显著低于Ⅲ、Ⅳ期患者(8.52±3.70)(P<0.05);研究组男性患者的血浆miRNA-625表达水平(0.58±0.48)显著高于女性患者(0.34±0.20),且Ⅰ、Ⅱ期患者的血浆miRNA-625表达水平(0.83±0.40)显著高于Ⅲ、Ⅳ期患者(0.45±0.47),差异均有统计学意义(P<0.05)。血浆miRNA-155、miRNA-625诊断NSCLC的敏感度(75.51%、73.47%)显著高于血清癌胚抗原(46.94%),差异有统计学意义(P<0.05)。结论NSCLC诊断中血浆miRNA-155、miRNA-625测定具有较高的临床价值。
Objective To study the clinical value of plasma miRNA-155 and miRNA-625 in the diagnosis of non-small cell lung cancer(NSCLC).Methods Using retrospective analysis methods,the study objects were 98 patients with NSCLC and 110 patients with benign lung diseases admitted to Beijing Shijitan Hospital,Capital Medical University from January 2018 to January 2020.They were set as the study group and the control group,respectively.The expression levels of miRNA-155,miRNA-625 and serum carcinoembryonic antigen levels were compared between the two groups,and the plasma miRNA-155,miRNA-625 expression and clinicopathological characteristics of the study group were analyzed(Gender,age,TNM stage,degree of differentiation,histological type,smoking)correlation,and compare the accuracy,negative predictive value,positive predictive value,specificity of miRNA-155,miRNA-625,serum carcinoembryonic antigen in the diagnosis of NSCLC And sensitivity.Results The levels of plasma miRNA-155 and serum carcinoembryonic antigen in the study group were 5.76±3.81,(6.62±5.41)μg/L,which were higher than the control group[1.98±1.71,(3.94±1.53)μg/L],plasma miRNA-625(0.53±0.43)was lower than the control group(1.08±0.61),and the differences were statistically significant(P<0.05).The teamⅠ,Ⅱperiod in patients with plasma miRNA-155(4.87±3.46)expression level was significantly lower thanⅢ,Ⅳperiod patients(8.52±3.70)(P<0.05).The plasma miRNA-625 expression level of male patients(0.58±0.48)in the study group was significantly higher than that of female patients(0.34±0.20),and the plasma miRNA-625 expression level of patients with stage I and II(0.83±0.40)was significantly higher than that ofⅢ,For stage IV(0.45±0.47),the difference was statistically significant(P<0.05).The sensitivity of plasma miRNA-155 and miRNA-625(75.51%,73.47%)in diagnosis of NSCLC was significantly higher than that of serum oncoembryonic antigen(46.94%),the difference was statistically significant(P<0.05).Conclusion The measurement of plasma miRNA-155 and miRNA-625 in the diagnosis of NSCLC has high clinical value.
作者
安志杰
方天露
张捷
潘磊
AN Zhi-jie;FANG Tian-lu;ZHANG Jie(Department of Respiratory and Critical Care Medicine,Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China)
出处
《临床和实验医学杂志》
2021年第7期718-721,共4页
Journal of Clinical and Experimental Medicine
基金
北京医卫健康公益基金会医学科学研究基金资助项目(编号:2017-A31)。
作者简介
通讯作者:安志杰,E-mail:anzhijie2955@bjsjth.cn。
